ArticleChemistry & biodiversity2026
Integrative In Silico and In Vitro Evaluation of Vialox and Leuphasyl Pentapeptides for Antiaging Applications.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Skin aging arises from intrinsic and extrinsic factors that drive extracellular matrix degradation, particularly of collagen and elastin, leading to wrinkles, pigmentation, and loss of skin elasticity. This is the first integrative study to evaluate the antiaging potential of the cosmeceutical pentapeptides Vialox and Leuphasyl using a combined approach of molecular docking, molecular dynamics simulations, and in vitro cytotoxicity assays. Targeting matrix metalloproteinases (MMP-1, MMP-8, and MMP-13), which contribute to collagen breakdown, and Sirtuin-1 (SIRT-1), a regulator of cellular longevity, the peptides were evaluated for binding affinity, stability, and structural dynamics. Docking and molecular dynamics studies revealed that Leuphasyl showed stronger interactions with MMP-13, while Vialox preferentially targeted SIRT-1, underscoring their potential to modulate aging-related pathways. In silico ADME and toxicity predictions suggested favorable pharmacokinetic and safety profiles. Furthermore, both peptides showed no cytotoxicity on HaCaT cell line at concentrations up to 1 mg/mL. This is the first integrative study to evaluate both peptides using combined computational and experimental approaches. Overall, these findings provide mechanistic insight into the anti-aging activity of Vialox and Leuphasyl and support their promise as effective, noninvasive dermocosmetic agents-offering a new avenue for healthier, youthful skin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.